Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection-Reference-Cited by-同舟云学术

Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection

Published:2022-05-15 Issue:1 Volume:2 Page:89-97
ISSN:2712-9179
Container-title:Personalized Psychiatry and Neurology
language:
Short-container-title:jour

Author:

Linova L. P.¹,Torgovtsev A. A.¹,Limankin O. V.¹,Nasyrova R. F.²

Affiliation:

1. P.P. Kashchenko Psychiatric Hospital N1

2. P.P. Kashchenko Psychiatric Hospital N1; V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology

Abstract

Schizophrenia is a common and socially significant mental disorder that requires longterm use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes and of Aps transport across the blood-brain barrier (BBB) and the cell membrane of APs target neurons in the brain. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. The aim of the case report is to present the experience of using PGx in a 36-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.

Publisher

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

Reference16 articles.

1. Katona, L.; Bitter, I.; Czobor, P. A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials? Transl Psychiatry 2021, 11(1), 510. doi: 10.1038/s41398-021-01636-9.

2. Kaar, S.J.; Natesan, S.; McCutcheon, R.; Howes, O.D. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 2020, 172, 107704. doi: 10.1016/j.neuropharm.2019.107704.

3. Kravtsov, V.V.; Filippov, I.A.; Vaiman, E.E.; Shnayder, N.A.; Nasyrova, R.F. Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2020, 120(7), 134-141. (In Russ.). https://doi.org/10.17116/jnevro2020120071134.

4. Nasyrova, R.F.; Schnaider, N.A.; Mironov, K.O.; Shipulin, G.A.; Dribnokhodova, O.P.; Golosov, E.A.; Tolmachev, M.Yu; Andreev, B.V.; Kurylev, A.A.; Akhmetova, L.Sh.; Limankin, O.V.; Neznanov, N.G. Pharmacogenetics of schizophrenia in real clinical practice: a clinical case. Neurology, Neuropsychiatry, Psychosomatics 2018, 10(4), 88–93. https://elibrary.ru/item.asp?id=36547318.

5. Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Oxidation of Antipsychotics. Encyclopedia 2022.